WHO should accelerate, not stall, rectal artesunate deployment for pre-referral treatment of severe malaria

© The Author(s) 2023. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene..

The recent World Health Organization moratorium on rectal artesunate (RAS) for pre-referral treatment of severe childhood malaria is costing young lives. The decision was based on disappointing findings from a large observational study that provided RAS to community health workers with little training and supervision. This non-randomized, operational research has provided useful information to guide the implementation of RAS but is subject to bias and confounding and cannot be used to assess treatment effects. Parenteral artesunate reduces severe malaria mortality and a large body of evidence also shows RAS has lifesaving efficacy. There is now more than a decade of delay in conducting the necessary engagement and training required for successful deployment of RAS. Further delays will result in more preventable deaths.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:117

Enthalten in:

Transactions of the Royal Society of Tropical Medicine and Hygiene - 117(2023), 7 vom: 04. Juli, Seite 536-538

Sprache:

Englisch

Beteiligte Personen:

Peto, Thomas J [VerfasserIn]
Watson, James A [VerfasserIn]
White, Nicholas J [VerfasserIn]
Dondorp, Arjen M [VerfasserIn]

Links:

Volltext

Themen:

60W3249T9M
Antimalarials
Artemisinins
Artesunate
Journal Article
Observational Study

Anmerkungen:

Date Completed 05.07.2023

Date Revised 06.07.2023

published: Print

Citation Status MEDLINE

doi:

10.1093/trstmh/trad002

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM352327847